ストックスクリーナーアプリを入手
3.01
1.63%
-0.05
前日終値:
$3.06
開ける：
$3.12
24時間の取引高:
1.02M
Relative Volume:
0.62
時価総額：
$274.45M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-8.267
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
-9.34%
1か月 パフォーマンス:
-6.23%
6か月 パフォーマンス:
-35.27%
1年 パフォーマンス:
+19.92%
1日の値動き範囲:
$3.01
$3.15
1週間の範囲:
$2.95
$3.37
52週間の値動き範囲:
$2.24
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.01 | 274.45M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics to Report Fourth Quarter 2024 - GlobeNewswire
Aquestive Therapeutics Q4 Earnings: Will New Business Updates Signal Growth Momentum? - StockTitan
Leerink maintains Aquestive Outperform rating, $13 target By Investing.com - Investing.com Canada
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Drop in Short Interest - Defense World
JMP Securities maintains $9 target on Aquestive Therapeutics stock By Investing.com - Investing.com Canada
Harvey Capital Management Inc. Buys 249,790 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00 - MarketBeat
Aquestive Therapeutics Inc (NASDAQ: AQST) Is A Blank Check For Growth - Stocks Register
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $11.00 Consensus Price Target from Analysts - MarketBeat
Aquestive Therapeutics to Present New Findings on Anaphylm™ - GlobeNewswire
Aquestive Therapeutics Announces Positive Stability and Efficacy Data for Anaphylm Epinephrine Sublingual Film at AAAAI Annual Meeting - Nasdaq
Breakthrough Allergy Treatment Shows 12-Min Response Time: Aquestive's Game-Changing Phase 2 Results - StockTitan
SG Americas Securities LLC Grows Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Wall Street analysts’ outlook for Aquestive Therapeutics Inc (AQST) - SETE News
Aquestive Therapeutics Inc [AQST] stock for 214 USD was sold by Jung Cassie - Knox Daily
Aquestive Therapeutics Inc (AQST) expanding its growth trajectory ahead - SETE News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Significant Increase in Short Interest - MarketBeat
Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart
Did Aquestive Therapeutics Inc (AQST) perform well in the last session? - US Post News
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
Piper starts Aquestive at overweight, cites allergy reaction treatment - MSN
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - MSN
Institutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Yahoo Finance
Cantor Fitzgerald Weighs in on AQST FY2025 Earnings - MarketBeat
Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 8.6% in December - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Anaphylaxis Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics - Barchart
Neuromuscular Disease Therapeutics Market to grow by USD 13.7 Billion from 2025-2029, driven by novel approvals, with AI impacting market trendsTechnavio - The Malaysian Reserve
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress - TipRanks
Aquestive Therapeutics Provides Business Update - citybiz
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives - The Manila Times
Aquestive Therapeutics Targets 2026 Launch for Anaphylm as FDA Approves Pediatric Seizure Drug - StockTitan
Aquestive Therapeutics: Five Foci For 2025 (NASDAQ:AQST) - Seeking Alpha
Geode Capital Management LLC Has $8.31 Million Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Barclays PLC Buys 73,542 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What Analysts Were Expecting After Aquestive Therapeutics Inc (NASDAQ: AQST) rose 4.21% - Stocks Register
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp - Defense World
State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
Aquestive Therapeutics Inc (AQST) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 15 '24 |
Sale |
6.00 |
50,000 |
300,000 |
984,476 |
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):